Issue StoriesThe Times Are a Changin'by Michael J. Breus, PhD, ABSM With new CMS guidelines going into effect on April 1, sleep specialists will have a secure set of rules for fee schedules and CPAP compliance
The previous Centers for Medicare & Medicaid Services (CMS) guidelines for nasal CPAP reimbursement covered individuals who met very specific respiratory and sleep criteria (30 episodes of apnea, with a duration of 10 seconds, during more than 6 hours of recorded sleep). These criteria were developed to identify those who had moderate to severe disease. The criteria were restrictive since we all have patients who have nothing but hypopneas (albeit 100/hour), 28 apneas, events that last only a few seconds, and events with a 3% desaturation or mild obstructive sleep apnea (OSA) with severe associated hypersomnia. These individuals could not receive a CPAP machine from CMS and in some instances could not get a CPAP titration. Also, since many third-party payors follow CMSs lead, many other patients were affected as well. Fortunately, the apnea rule has been reconsidered and new guidelines have been published, thanks to the tireless work of professional associations, manufacturers, and clinicians. New Criteria 1) An apnea-hypopnea index (AHI) of 15 events per hour, or 2) An apnea index 5 and 14 events with documented symptoms including excessive daytime sleepiness, impaired cognition, mood disorders, or insomnia, or documented hypertension, ischemic heart disease, or history of stroke. AHI is defined as the average number of episodes of apnea and hypopnea per hour based on a minimum of 2 hours of sleep recorded by polysomnography using actual, not projected, hours of sleep. Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event, lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, with at least 4% oxygen desaturations. Polysomnography must be performed in a facility-based sleep laboratory. A full version of this coverage decision can be found at www.hcfa.gov/coverage/8b3-bbb.htm. It should be noted that these new guidelines might still allow for a sleepy person (those who had respiratory arousals only) who could benefit from CPAP to slip through the cracks; however, we all must applaud these tireless efforts and continue the battle. Physicians should also understand the coverage criteria for home-based bilevel PAP machines. The necessary criteria for bilevel PAP prescription are: 1) A facility-based, attended polysomnogram with an established diagnosis of OSA, and 2) a single-level device (E0601, CPAP) that has been tried and proven ineffective. There does not appear to be a definition of what ineffective may mean. Once this situation is documented by a physician, bilevel PAP should be easily obtained (in some states for only 3 monthscheck with your local provider). We at SCMI have found practices that have identified those patients who have suffered from the apnea rule in the past and simply tried CPAP (loaned to them by the physician or local durable medical equipment [DME] company) and had it fail. At that point, the practice would request a bilevel PAP with a 0-1 cm difference between the inspiratory and expiratory pressuresin essence, creating a CPAP and thus allowing the patient to receive treatment despite not having 30 apneas. These practices were found to be legal in these states; however, the obvious intent was to skirt around the apnea rule. Although these practices were legal, ethics may prevent their use in a sleep center. The new CMS guidelines for CPAP treatment will take effect on April 1, 2002, and will not be retroactive. Thus, the old apnea rule stands until March 31. The fact that these new criteria are not retroactive may represent an interesting opportunity for possible increased revenue. That is, if a practice were able to identify CMS patients who previously did not get a CPAP, but still have symptoms of sleep disordered breathing, a polysomnogram and/or subsequent CPAP titration may be in order. In some states, CMS requires that a diagnostic study be no older than 90 days. Generally, these studies do not require precertification. Therefore, some practices seem to be identifying these patients, contacting them, seeing if they are still symptomatic, and trying to get a diagnostic sleep study and eventually a CPAP titration. It should be noted that there are no clear data on whether this strategy will work, and it may be necessary to review payout of services before continuing on a large scale. These criteria may also represent a possible increased revenue for DME companies as well. With these new guidelines, CMS has also requested that carriers develop a method for monitoring compliance for CPAP devices. Although this is the first request by CMS, this is not something new for many carriers. For example, compliance programs are often included in contract negotiations, and carriers will hold payment until compliance has been established. The definition of compliance may vary from carrier to carrier. In dealing with contract negotiations for many sleep centers, we have offered several different programs to validate compliance for the company as well as payment for the sleep center or DME provider. Treatment Compliance Follow-Up Conversion Factor Conclusion Remember that all the information within this article represents suggestions and does not substitute for sound legal advice. Contact health care attorneys in your state for review of all situations or changes in policy. With CMS requesting information on ways to increase compliance, we may now have found a new era of sophistication. Thus, sleep specialists need to continue to develop and redevelop new practices for compliance, yet still maintain a financially viable sleep center. Michael J. Breus, PhD, ABSM, is a senior partner and founder of The Sleep Center Management Institute, Atlanta; (888) 556-2203; mbreus@sleepcmi.com; www.sleepcentermanagement.com. |
|
|
|
ADDITIONAL ONLINE RESOURCES |
|